About

Pipeline

Partnership

Newsroom

Careers

Contact

中
banner1(1)-306.jpg banner2(1)-557.jpg
Bridging the gap between unmet patient needs and
Read More
Abanner2.jpg 01.jpg
From science to medicine, we commit to bring
Read More

LATEST NEWS

October 31, 2023
AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery

LATEST NEWS

October 10, 2023
AffaMed Technologies Announces Licensing of EVOLUX®- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL

LATEST NEWS

September 25, 2023
AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD

LATEST NEWS

September 20, 2023
AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA ® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
Our Areas of Focus
We are advancing a strong group of innovative clinical assets in ophthalmology, neurology & psychiatry. These drug candidates provide us a risk-balanced portfolio in a mix of major disease states characterized by high unmet patient needs.
Ophthalmology
Neurology & Psychiatry
Who We Are
AffaMed Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs in ophthalmology, neurology and psychiatric disorders. We hope to bring the benefit of our products to patients in Greater China and around the world.
Read More
Strong Leadership Team of Seasoned Executives
Extensive Global Network
Deep Insights into Ophthalmology, Neurology & Psychiatry

Newsroom

October 31, 2023
AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery
Read More
October 10, 2023
AffaMed Technologies Announces Licensing of EVOLUX®- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL
September 25, 2023
AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD
September 20, 2023
AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA ® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery